311690 — CJ Bioscience Income Statement
0.000.00%
Last trade - 00:00- KR₩123bn
- KR₩76bn
- KR₩3bn
Annual income statement for CJ Bioscience, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 5,312 | 4,363 | 4,075 | 5,575 | 3,467 |
| Cost of Revenue | |||||
| Gross Profit | 2,415 | 1,653 | 1,406 | 1,843 | 365 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Depreciation and Amortization | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 13,825 | 16,606 | 37,308 | 37,556 | 37,708 |
| Operating Profit | -8,513 | -12,243 | -33,233 | -31,981 | -34,241 |
| Gain / Loss on Sale of Assets | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -8,763 | -19,272 | -34,913 | -22,913 | -32,838 |
| Net Income After Taxes | -8,763 | -19,272 | -34,913 | -22,913 | -32,838 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -8,763 | -19,272 | -34,913 | -22,913 | -32,838 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -8,763 | -19,272 | -34,913 | -22,913 | -32,838 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1,928 | -3,459 | -5,040 | -3,245 | -3,542 |
| Dividends per Share |